Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04228419
Other study ID # 20190674-01H
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 9, 2020
Est. completion date December 31, 2028

Study information

Verified date April 2024
Source Ottawa Hospital Research Institute
Contact Peter Lapner Lapner, MD
Phone 613-737-8899
Email plapner@toh.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare total shoulder arthroplasty (TSA) reverse shoulder arthroplasty (RSA) procedures, in the context of a prospective, randomized-controlled trial to determine the optimal treatment in patients 65 years of age and older, and equal to or less than 15 degrees of glenoid retroversion, who have glenohumeral osteoarthritis.


Description:

Osteoarthritis (OA) of the shoulder is a disease resulting from the wearing down of cartilage over time. OA can be the cause of pain and dysfunction and is a growing occurrence in the investigator's aging population. TSA or RSA are common surgical procedures used to treat patients with shoulder OA. TSA is able to keep the "natural anatomy" of the shoulder and involves replacing the worn-out ball and socket shoulder joint with prosthetic components. TSA is performed today with high success rates, however, complication rates associated with TSA remain prevalent, particularly when the arthritis is associated with bone erosion on the glenoid (socket). RSA is an alternative surgical procedure commonly used and involves replacing and reversing the ball and the socket (i.e. opposite of TSA). RSA is typically performed in patients with a rotator cuff deficiency and more severe OA. Though RSA procedures show marked increase in clinical and functional outcomes, evidence of its long-term results are sparse, and as such is typically reserved for when treating an older patient population. Few research studies have compared these different surgical techniques to one another, in the older patient population. This research will provide surgeons with new information regarding the best treatment for patients in this population. This Randomized Controlled Trial (RCT) will compare TSA and RSA procedures in those 65 years of age and older, who have equal to or less than 15 degrees of glenoid retroversion, in an effort to determine which approach produces better functional outcomes and improved quality of life in this patient population. Primary Objective: Determine the difference in disease specific quality of life between patients diagnosed with glenohumeral OA who undergo either a TSA or RSA as measured by the Western Osteoarthritis of the Shoulder (WOOS) score at 24-months and 5-years post-operative. Secondary Objectives: i) Determine the difference in disease specific quality of life between patients diagnosed with a glenohumeral osteoarthritis who undergo a shoulder replacement with RSA or TSA as measured by the Constant score, the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment form (ASES), the EuroQol Group EQ-5D-5L score, pain (using a Visual Analog Scale), and Subjective Shoulder Value (SSV) at 24-months and 5-years post-operative as well as adverse events, and health care utilization. ii) To determine the survivorship of the components as measured by the degree of radiographic lucencies and component alignment determined by a CT scan at 1- and 5-years post-surgery. Clinical Relevance: Shoulder OA results in pain and dysfunction, which negatively impacts quality of life. As such, determination of superior treatment approach will lead to significant improvement in quality of life, and cost savings through avoidance of recurrence and/or reoperation, as well as decreased morbidity for patients in this population.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date December 31, 2028
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. Patients who have failed standard non-surgical management of their idiopathic shoulder osteoarthritis who would benefit from a shoulder arthroplasty. Failed medical management will be defined as persistent pain and disability despite adequate standard non-operative management for 6 months. Medical management will be defined as: 1. The use of drugs including analgesics and non-steroidal anti-inflammatory drugs 2. Physiotherapy consisting of stretching, strengthening and local modalities (ultrasound, cryotherapy, etc.) 3. Activity modification 2. Imaging, and intra-operative findings confirming advanced glenohumeral cartilage loss 3. Patients may present with a glenoid deficiency and </=15 degrees of retroversion 4. 65 years of age and older Exclusion Criteria: 1. Active joint or systemic infection 2. Rotator cuff arthropathy 3. Significant muscle paralysis 4. Charcot's arthropathy 5. Major medical illness (life expectancy less than 1 year or unacceptably high operative risk) 6. Unable to understand the consent form/process 7. Pregnancy 8. Psychiatric illness that precludes informed consent 9. Unwilling to be followed for the duration of the study 10. Retroversion cannot be surgically corrected to within 10 degrees of neutral 11. History of previous shoulder surgery on affected side

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Total Shoulder Arthroplasty
Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
Reverse Shoulder Arthroplasty
Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta
Canada Kingston General Hospital (Site-Watkins 3) Kingston Ontario
Canada The Ottawa Hospital Ottawa Ontario
Canada Pan Am Clinic Foundation Winnipeg Manitoba

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Western Ontario Osteoarthritis of the Shoulder Index (WOOS) The Western Ontario Osteoarthritis of the Shoulder Index (WOOS) is a disease specific evaluation, proven to be an accurate and valid assessment of function after shoulder replacement. The WOOS is a patient-reported measure, 19-question survey. Each question is measured using a visual analog scale rated from 0-100, where higher scores mean better outcome. 24-Months and 5-Years Post-Operative
Secondary Standard CT Scans Radiological parameters will be examined using Computed Tomography (CT). These scans will be analyzed for abnormalities in component alignment, and evidence of lucencies or loosening. Higher incidence of loosening, or noted abnormalities will be compared between groups. A higher incidence indicates worse outcomes. 24-Months and 5-Years Post-Operative
Secondary American Shoulder and Elbow Surgeons Standardized Shoulder Assessment form (ASES) The ASES is a shoulder specific assessment divided into two sections: pain and activities of daily living (ADL). Pain is recorded on a visual analogue scale (0-10), lower scores indicate better outcomes. There are 10 activities of daily living questions, each are recorded on a 4 level likert scale (0-3), which a higher score indicates a better outcome. The overall score is an equal weight of the two sections and produces a score out of 100. The higher the score, the better the outcome. 24-Months and 5-Years Post-Operative
Secondary Pain Level Subjective pain value of the shoulder will be assessed using a questionnaire. Pain is recorded on a visual analogue scale (0-10), lower scores indicate better outcomes. The higher the score, the worse the outcome. 24-Months and 5-Years Post-Operative
Secondary Subjective Shoulder Value A participant's subjective value on shoulder function will be assessed using a questionnaire. The overall functional value of the shoulder is written as a percentage from 0-100% of a normal shoulder. The higher the score, the better the outcome. 24-Months and 5-Years Post-Operative
Secondary EuroQol EQ-5D-5L The EQ-5D-5L quality of life questionnaire is a brief, easy to administer generic health status questionnaire, consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses (each question rated 1-5), lower scores indicate better outcome. It also includes a visual analogue scale for recording an individual's rating of their current health-related quality of life (scale 0 to 100), where a higher score indicates a better outcome. 24-Months and 5-Years Post-Operative
Secondary Constant Score The Constant Score reflects an overall clinical functional assessment. This instrument is based on a 100-point scoring system. Subjective findings (pain, activities of daily living, and working in different positions) make up a total of 35 points. Objective measurements make up the remaining 65 points.The test is divided into four sub-categories: (1) pain is measured using 4 likert levels (15 points maximum), where a higher score indicates a better outcome; activities of daily living are measured using a likert scale, where a higher number indicates better outcomes (20 points maximum); mobility is measured by an assessor, and rated using a likert scale where a higher score indicates better outcomes (40 points maximum); finally, strength is measured by an assessor where 1 point is given per 0.5kg of force (maximum 25 points), a higher score indicates better outcomes. All categories are added together, and a total score out of 100 is given (higher score indicates better outcome). 24-Months and 5-Years Post-Operative
Secondary Adverse Events (AE) and Serious Adverse Events (SAE) Rates of study adverse events or serious adverse events (e.g. number of reoperations) will be monitored and recorded and compared between study groups. A higher rate of adverse events indicates a worse outcome. 24-Months and 5-Years Post-Operative
Secondary Health Care Utilization Health care utilization will be monitored and recorded using a questionnaire. These questions will include healthcare the patient accessed, cost of care, and medications taken during treatment. From this information, a cost-effectiveness analysis will be completed, which will adhere to the best practices for conducting and reporting of health economic evaluations. 24-Months and 5-Years Post-Operative
See also
  Status Clinical Trial Phase
Recruiting NCT05160441 - Comparing Platelet Rich Plasma and Corticosteroid for Military & Civilian Patients With Glenohumeral Osteoarthritis Phase 3
Suspended NCT02204228 - TITAN™ Reverse Shoulder System
Recruiting NCT04468178 - Clinical Results and RSA Migration Analysis of the GLOBAL ICON - Stemless Anatomic Shoulder N/A
Withdrawn NCT03770546 - Amnion-Based Injections in the Shoulder N/A
Active, not recruiting NCT05049993 - Pyrocarbon Clinical Follow-up Study
Terminated NCT04160091 - Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis Phase 2
Completed NCT00479687 - SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder N/A
Enrolling by invitation NCT03404778 - Comprehensive Reverse Shoulder Data Collection
Completed NCT02052206 - Reconstruction of Complex Proximal Humeral Fractures. N/A
Completed NCT03887650 - LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs Phase 4
Active, not recruiting NCT04634773 - Unravelling the Etiology of Shoulder Osteoarthritis N/A
Completed NCT01697865 - Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction N/A
Enrolling by invitation NCT03806881 - Long Term Follow-up After Primary or Revision Shoulder Arthroplasty With a Patient- Specific Glenius Implant
Active, not recruiting NCT01587560 - A Comparison Between a Pyrocarbon and a CoCr Shoulder Resurfacing Implant N/A
Completed NCT03385408 - Effectiveness of HILT in Shoulder Osteoarthritis N/A
Active, not recruiting NCT03097406 - Functional Outcome and Complications After Global Unite ® Prostheses
Active, not recruiting NCT03409718 - Database Retrieval for the Comprehensive Shoulder
Withdrawn NCT04134442 - Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome Phase 4
Completed NCT03382262 - Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip Phase 2
Active, not recruiting NCT03726554 - Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder Arthroplasty N/A